$1.76
-0.01 (-0.57%)
Open$1.81
Previous Close$1.77
Day High$1.82
Day Low$1.73
52W High$3.54
52W Low$1.22
Volume—
Avg Volume2.04M
Market Cap166.62M
P/E Ratio—
EPS$-1.42
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+359.1% upside
Current
$1.76
$1.76
Target
$8.08
$8.08
$6.79
$8.08 avg
$13.52
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.85M | 12.74M | 54.83M |
| Net Income | -157,310,323 | -152,153,993 | 10.00M |
| Profit Margin | -1,327.4% | -1,261.0% | 18.2% |
| EBITDA | -163,400,011 | -166,824,299 | 16.80M |
| Free Cash Flow | — | — | 9.93M |
| Rev Growth | -7.0% | -7.0% | -2.4% |
| Debt/Equity | — | — | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |